Cargando…

High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study

BACKGROUND: Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL/METHODS: Newly diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaorong, Xu, Yan, Zhang, Wanggang, Wang, Jin, Cao, Xingmei, Chen, Yinxia, He, Aili, Liu, Jie, Wang, Jianli, Zhao, Wanhong, Yang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913830/
https://www.ncbi.nlm.nih.gov/pubmed/27232105
http://dx.doi.org/10.12659/MSM.895383
_version_ 1782438466088337408
author Ma, Xiaorong
Xu, Yan
Zhang, Wanggang
Wang, Jin
Cao, Xingmei
Chen, Yinxia
He, Aili
Liu, Jie
Wang, Jianli
Zhao, Wanhong
Yang, Yun
author_facet Ma, Xiaorong
Xu, Yan
Zhang, Wanggang
Wang, Jin
Cao, Xingmei
Chen, Yinxia
He, Aili
Liu, Jie
Wang, Jianli
Zhao, Wanhong
Yang, Yun
author_sort Ma, Xiaorong
collection PubMed
description BACKGROUND: Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL/METHODS: Newly diagnosed DLBCL patients <60 years old who were treated at the Second Hospital Affiliated with Xi’an Jiaotong University between January 2004 and December 2013 (n=198, 18–60 years) were included in the study. The high-intensity group included 107 patients (54.0%) who received >8 courses of chemotherapy (high-dose CHOP, CHOP-E, EPOCH, MAED, MMED, and HyperCVAD). The control group included 91 patients (46.0%) who received 6–8 courses of CHOP-based treatment. Response rate (RR), survival, relapse, and adverse effects were compared. RESULTS: Baseline characteristics of the patients were similar between the 2 groups. Median follow-up was 64.5 months. RR in the high-intensity and control groups was 88.8% and 84.6% (P=0.387), respectively; 5-year overall survival was 66.4% and 36.3% (P<0.001), respectively; 5-year progression-free survival was 56.1% and 28.6% (P<0.001), respectively; 5-year disease-free survival was 54.2% and 24.2% (P<0.001), respectively; and relapse rate during follow-up was 29.5% and 67.5% (P<0.001), respectively. There were no significant differences in adverse effects between the 2 groups. CONCLUSIONS: High-intensity chemotherapy is associated with better prognosis of patients <60 years old with newly diagnosed high-risk DLBCL.
format Online
Article
Text
id pubmed-4913830
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-49138302016-06-28 High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study Ma, Xiaorong Xu, Yan Zhang, Wanggang Wang, Jin Cao, Xingmei Chen, Yinxia He, Aili Liu, Jie Wang, Jianli Zhao, Wanhong Yang, Yun Med Sci Monit Clinical Research BACKGROUND: Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL/METHODS: Newly diagnosed DLBCL patients <60 years old who were treated at the Second Hospital Affiliated with Xi’an Jiaotong University between January 2004 and December 2013 (n=198, 18–60 years) were included in the study. The high-intensity group included 107 patients (54.0%) who received >8 courses of chemotherapy (high-dose CHOP, CHOP-E, EPOCH, MAED, MMED, and HyperCVAD). The control group included 91 patients (46.0%) who received 6–8 courses of CHOP-based treatment. Response rate (RR), survival, relapse, and adverse effects were compared. RESULTS: Baseline characteristics of the patients were similar between the 2 groups. Median follow-up was 64.5 months. RR in the high-intensity and control groups was 88.8% and 84.6% (P=0.387), respectively; 5-year overall survival was 66.4% and 36.3% (P<0.001), respectively; 5-year progression-free survival was 56.1% and 28.6% (P<0.001), respectively; 5-year disease-free survival was 54.2% and 24.2% (P<0.001), respectively; and relapse rate during follow-up was 29.5% and 67.5% (P<0.001), respectively. There were no significant differences in adverse effects between the 2 groups. CONCLUSIONS: High-intensity chemotherapy is associated with better prognosis of patients <60 years old with newly diagnosed high-risk DLBCL. International Scientific Literature, Inc. 2016-05-27 /pmc/articles/PMC4913830/ /pubmed/27232105 http://dx.doi.org/10.12659/MSM.895383 Text en © Med Sci Monit, 2016 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
spellingShingle Clinical Research
Ma, Xiaorong
Xu, Yan
Zhang, Wanggang
Wang, Jin
Cao, Xingmei
Chen, Yinxia
He, Aili
Liu, Jie
Wang, Jianli
Zhao, Wanhong
Yang, Yun
High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
title High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
title_full High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
title_fullStr High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
title_full_unstemmed High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
title_short High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
title_sort high-intensity chemotherapy is associated with better prognosis in young patients with high-risk diffuse large b-cell lymphoma: a 10-year single-center retrospective cohort study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913830/
https://www.ncbi.nlm.nih.gov/pubmed/27232105
http://dx.doi.org/10.12659/MSM.895383
work_keys_str_mv AT maxiaorong highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT xuyan highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT zhangwanggang highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT wangjin highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT caoxingmei highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT chenyinxia highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT heaili highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT liujie highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT wangjianli highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT zhaowanhong highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy
AT yangyun highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy